<!DOCTYPE html><html lang="en" class="page"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1"><link rel="shortcut icon" href="favicon.ico" type="image/x-icon"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta name="theme-color" content="#111111"><title>CoSense® ETCOc Monitoring: Transformative Jaundice Management for Newborns</title><meta name="description" content="Explore CoSense® ETCO Monitor: Transforming neonatal care with non-invasive bilirubin monitoring. AAP-aligned strategies for confident discharges and optimized newborn health. Meet expert advisors and discover clinical evidence for better outcomes."><meta property="og:type" content="website"><meta property="og:locale" content="en_US"><meta property="og:title" content="CoSense® ETCOc Monitoring: Transformative Jaundice Management for Newborns"><meta property="og:description" content="Explore CoSense® ETCO Monitor: Transforming neonatal care with non-invasive bilirubin monitoring. AAP-aligned strategies for confident discharges and optimized newborn health. Meet expert advisors and discover clinical evidence for better outcomes."><meta property="og:image" content="https://ibb.co/VgZvzgF"><meta property="twitter:card" content="summary_large_image"><meta property="twitter:title" content="CoSense® ETCOc Monitoring: Transformative Jaundice Management for Newborns"><meta property="twitter:description" content="Explore CoSense® ETCO Monitor: Transforming neonatal care with non-invasive bilirubin monitoring. AAP-aligned strategies for confident discharges and optimized newborn health. Meet expert advisors and discover clinical evidence for better outcomes."><meta property="twitter:image" content="https://ibb.co/VgZvzgF"><meta name="robots" content="all"><meta name="author" content="Capnia"><link rel="preload" href="fonts/WorkSansRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansMedium.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansBold.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowBold.woff2" as="font" type="font/woff2" crossorigin><link rel="stylesheet" href="css/vendor.css"><link rel="stylesheet" href="css/main.css"><script defer="defer" src="js/main.js"></script></head><body class="page__body"><a class="skiplink" href="#main">Go to main content</a><div class="site-container"><header class="header header--products"><div class="header__container container-additional"><a class="header__logo" href="index.html"><img src="./img/logo.svg" class="header__logo-image" width="176" height="40" alt="Capnia logo"></a><nav class="header__nav" aria-label="Main navigation" data-menu><ul class="header__nav-list"><li class="header__nav-item"><a class="header__nav-link header__nav-link--home" href="index.html">Home</a></li><li class="header__nav-item"><a class="header__nav-link" href="products.html"><i>CoSense <span>®</span> </i>Product</a></li><li class="header__nav-item header__nav-item--dropdown"><button class="header__nav-link js-btn-dropdown" type="button" aria-label="Open submenu navigation">Clinical Resources</button><div class="dropdown"><div class="dropdown__wrapper"><ul class="dropdown__list"><li class="dropdown__item"><a class="dropdown__link dropdown__link--studies" href="cosense-studies.html"><span class="dropdown__link-text"><i>CoSense <span>®</span> </i></span>Studies</a></li><li class="dropdown__item"><a class="dropdown__link" href="bibliography.html">Bibliography</a></li><li class="dropdown__item"><a class="dropdown__link" href="guidelines.html">Guidelines</a></li></ul></div></div></li><li class="header__nav-item"><a class="header__nav-link" href="about.html">About Us</a></li><li class="header__nav-item"><a class="header__nav-link header__nav-link--contact" href="#">Contact Us</a></li></ul></nav><button class="header__burger" aria-label="Open menu" aria-expanded="false" data-burger><span class="header__burger-line"></span></button></div></header><main class="page__main" id="main"><section class="page-hero"><div class="page-hero__container container"><h1 class="visually-hidden">Capnia: Revolutionary technology to improve newborn health care!</h1><div class="page-hero__swiper swiper"><div class="swiper-wrapper"><div class="swiper-slide"><div class="page-hero__wrapper"><div class="page-hero__content"><h2 class="page-hero__title title-huge">Jaundice Management is complex but improving outcomes is easier than you think with ETCOc Testing.</h2><div class="page-hero__inner"><div class="page-hero__info text-huge"><p>A simple breath test, the <i>CoSense <span>®</span> </i>ETCOc Monitor provides early and accurate measurement of hemolysis and neurotoxic risk that can lead to hemolytic hyperbilirubinemia (HB) and kernicterus.</p><p><b>AAP Guideline:</b> “ETCOc is the only test that can confirm the presence or absence of hemolysis and measure the rate of bilirubin production.”</p></div><a class="page-hero__link link link--yellow" href="#">Review AAP Guidelines</a></div></div><div class="page-hero__images"><img class="page-hero__decor" src="./img/decor-light-bg.svg" alt="" width="820" height="820" aria-hidden="true"><picture class="page-hero__picture"><source srcset="./img/page-hero-img/page-hero-slider-1.webp" type="image/webp"><img src="./img/page-hero-img/page-hero-slider-1.jpg" class="page-hero__image" width="672" height="672" alt="Newborn baby lying in a crib"></picture></div></div></div><div class="swiper-slide"><div class="page-hero__wrapper"><div class="page-hero__content"><h2 class="page-hero__title title-huge">Evaluate each newborn’s bilirubin neurotoxicity risk to send them home with confidence.</h2><div class="page-hero__inner"><div class="page-hero__info text-huge"><p>Most babies readmitted for hyperbilirubinemia (HB) are considered low risk at the time of discharge. Universal testing with the non-invasive <i>CoSense <span>®</span> </i>ETCOc monitor before discharge identifies babies with hemolytic conditions who may be at high risk of neurotoxicity.</p></div><a class="page-hero__link link link--yellow" href="products.html">Learn More</a></div></div><div class="page-hero__images"><img class="page-hero__decor" src="./img/decor-light-bg.svg" alt="" width="820" height="820" aria-hidden="true"><picture class="page-hero__picture"><source srcset="./img/page-hero-img/page-hero-slider-2.webp" type="image/webp"><img src="./img/page-hero-img/page-hero-slider-2.jpg" class="page-hero__image" width="672" height="672" alt="The doctor will examine the newborn"></picture></div></div></div><div class="swiper-slide"><div class="page-hero__wrapper"><div class="page-hero__content"><h2 class="page-hero__title title-huge">ETCOc testing of EVERY baby before discharge decreases readmissions, unnecessary needlesticks, phototherapy, and costs.</h2><div class="page-hero__inner"><div class="page-hero__info text-huge"><p>An ETCOc test, combined with TcB/TSB measurement, for all babies before discharge or during phototherapy treatment has proven to:</p><ul><li>Prevent readmission for hyperbilirubinemia (HB) and mother/baby separation. <a href="cosense-studies.html#test-226">(Bao 2022)</a></li><li>50% reduction in blood tests <a href="cosense-studies.html#test-231">(Elsaie 2020)</a> <a href="cosense-studies.html#test-228">(Bahr 2021)</a></li><li>20% reduction in photo therapy and improved utilization. <a href="cosense-studies.html#test-172">(Yang 2023)</a></li><li>Reduced <a href="cosense-studies.html#test-228">(Bahr. 2021)</a></li></ul></div></div></div><div class="page-hero__images"><img class="page-hero__decor" src="./img/decor-light-bg.svg" alt="" width="820" height="820" aria-hidden="true"><picture class="page-hero__picture"><source srcset="./img/page-hero-img/page-hero-slider-3.webp" type="image/webp"><img src="./img/page-hero-img/page-hero-slider-3.jpg" class="page-hero__image" width="672" height="672" alt="ETCO apparatus for newborn screening"></picture></div></div></div><div class="swiper-slide"><div class="page-hero__wrapper"><div class="page-hero__content"><h2 class="page-hero__title title-huge">Know the facts when managing jaundice. ETCOc is the evidence-based gold standard for diagnosing hemolysis and endorsed by AAP.</h2><div class="page-hero__inner"><div class="page-hero__info text-huge"><p><b>AAP Guideline:</b> Lower gestational age and hemolytic disease are risk factors for developing significant hyperbilirubinemia and for bilirubin neurotoxicity. Identify and quantify hemolysis EARLY, provide the necessary treatment, and send them home safe</p></div><a class="page-hero__link link link--yellow" href="#">Review AAP Guidelines</a></div></div><div class="page-hero__images"><img class="page-hero__decor" src="./img/decor-light-bg.svg" alt="" width="820" height="820" aria-hidden="true"><picture class="page-hero__picture"><source srcset="./img/page-hero-img/page-hero-slider-4.webp" type="image/webp"><img src="./img/page-hero-img/page-hero-slider-4.jpg" class="page-hero__image" width="672" height="672" alt="Young family together with a newborn baby"></picture></div></div></div></div><div class="page-hero__swiper-pagination swiper-pagination"></div></div></div></section><section class="monitoring"><div class="container"><h2 class="monitoring__title title-medium">The <i>CoSense <span>®</span> </i>ETCOc (end-tidal carbon monoxide) test is the non-invasive, rapid, and proven way to identify high-risk hemolytic cases from newborns with harmless jaundice prior to discharge.</h2><div class="monitoring__wrapper"><div class="monitoring__images"><picture class="monitoring__picture"><source srcset="./img/monitoring-img/monitoring-image.webp" type="image/webp"><img class="monitoring__image" loading="lazy" src="./img/monitoring-img/monitoring-image.jpg" width="733" height="451" alt="The newborn is tested through the endogenous carbon monoxide (ETCO) CoSense®"></picture></div><div class="monitoring__info"><div class="monitoring__text text-medium"><p>In less than 5 minutes, the <i>CoSense <span>®</span> </i>ETCOc Monitor detects the rate of hemolysis through non-invasive ETCOc testing of a newborn’s breath to accurately detect and measure the overproduction of unconjugated bilirubin and provide clear guidance for jaundice management.</p></div><a class="monitoring__link link link--yellow" href="products.html">Learn More</a></div></div></div></section><section class="jaundice"><div class="container"><div class="jaundice__wrapper"><div class="jaundice__info"><h2 class="jaundice__title title-small">Jaundice Management 101: Understand the ins and outs of bilirubin imbalance.</h2><div class="jaundice__text text-medium"><p>Excess bilirubin accumulates in newborns for three reasons:</p><ul><li><span>Over production</span> due to an underlying hemolytic condition.</li><li><span>Impaired conjugation</span> due to limited function of an immature liver.</li><li><span>Impaired elimination</span> due to problems with feeding or excretion.</li></ul><p>Prior to ETCOc tests, increased production of neurotoxic unconjugated bilirubin was difficult to detect until symptoms were evident, putting newborns at elevated risk for <button class="jaundice__button button-modal js-open-modal" type="button" aria-label="Open kernicterus modal" title="Open kernicterus modal">kernicterus</button> and requiring immediate phototherapy.</p><dialog class="jaundice__dialog dialog js-modal" aria-labelledby="dialog-header-kernicterus" aria-describedby="dialog-content-kernicterus"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close kernicterus modal" title="Close kernicterus modal" autofocus><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content dialog__modal-content--kernicterus"><div class="dialog__modal-inner"><h3 class="dialog__modal-title visually-hidden" id="dialog-header-kernicterus">Adverse Neurodevelopmental Outcomes and Risk Factors Associated with Neonatal Jaundice</h3><div class="dialog__modal-text text-medium" id="dialog-content-kernicterus"><p>Adverse neurodevelopmental outcomes from jaundice may include Kernicterus (KI), Low IQ, auditory anomalies, and respiratory failure.</p><p>KI is a life-threatening condition caused by Bilirubin toxicity to parts of the brain. Short hospital stays contribute to KI cases as newborns are discharged at 48-72 hours after birth while TsB peaks at 3-5 days of age, making bilirubin management an outpatient problem. Other risk factors include the failure to check bilirubin or diagnose a hemolytic condition in jaundiced infants in first 24 hours and the failure to recognize risk factors.</p></div></div></div></dialog></div></div><div class="jaundice__swiper swiper"><div class="swiper-wrapper"><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-1.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-1.jpg" class="jaundice__image" width="765" height="430" alt="Stage one - the red blood cell breaks down, bilirubin and carbon monoxide enter the bloodstream."></picture><figcaption>When a red blood cell lyses, bilirubin and carbon monoxide are released into the bloodstream.</figcaption></figure></div><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-2.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-2.jpg" class="jaundice__image" width="765" height="430" alt="Stage two - The carbon monoxide conjugates with hemoglobin and is exhaled through the lungs."></picture><figcaption>The carbon monoxide conjugates with hemoglobin and is exhaled through the lungs.</figcaption></figure></div><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-3.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-3.jpg" class="jaundice__image" width="765" height="430" alt="Stage three - The bilirubin is conjugated in the liver and excreted"></picture><figcaption>The bilirubin is conjugated in the liver and excreted. The newborn liver can manage a normal level of hemolysis.</figcaption></figure></div><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-4.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-4.jpg" class="jaundice__image" width="765" height="430" alt="Stage four - hemolysis rises, the liver is unable to keep pace with bilirubin production."></picture><figcaption>But if the rate of hemolysis rises, the liver is unable to keep pace with bilirubin production.</figcaption></figure></div><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-5.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-5.jpg" class="jaundice__image" width="765" height="430" alt="Stage five - Accumulated bilirubin may pass through the blood-brain barrier to the central nervous system, creating neurologic damage."></picture><figcaption>At high levels, accumulating unconjugated bilirubin may pass through the blood-brain barrier to the central nervous system, creating neurologic damage.</figcaption></figure></div><div class="swiper-slide"><figure class="jaundice__figure text-medium"><picture class="jaundice__picture"><source srcset="./img/jaundice-img/jaundice-step-6.webp" type="image/webp"><img loading="lazy" src="./img/jaundice-img/jaundice-step-6.jpg" class="jaundice__image" width="765" height="430" alt="With CoSense, hemolysis is detected and monitored to manage jaundice interventions."></picture><figcaption>The best indicator of active hemolysis can be measured from exhaled breath through elevated end-tidal carbon monoxide ETCOc levels. With <i>CoSense <span>®</span> </i>, hemolysis is detected and monitored to manage jaundice interventions.</figcaption></figure></div></div><div class="jaundice__swiper-pagination swiper-pagination"></div></div></div></div></section><section class="jaundice-treatment"><div class="jaundice-treatment__container container"><h2 class="visually-hidden">Assessment and Management of Neonatal Jaundice: Integrating Hemolysis Impact Measurement and ETCOc as a Gold Standard Diagnostic Test</h2><div class="jaundice-treatment__content"><h3 class="jaundice-treatment__title title-small">How are you measuring the impact of hemolysis on bilirubin management?</h3><div class="jaundice-treatment__text text-medium"><p>A common protocol is to perform one or more transcutaneous bilirubin (TCB) tests on every baby within the first 24 hours. When jaundice is suspected, an invasive total serum bilirubin (TSB) test is required.</p><p>However, these <button class="jaundice-treatment__button button-modal js-open-modal" type="button" aria-label="Open blood tests modal" title="Open blood tests modal">blood tests</button> can be unreliable in identifying cases of over unconjugated bilirubin production because they reflect all bilirubin in the blood. A high TSB/TCB level could indicate elevated production, decreased conjugation of bilirubin in the liver, or decreased excretion of conjugated bilirubin. Thus, TSB/TCB testing alone is not sufficient for Jaundice management.</p><p>We cannot improve what we cannot measure.</p></div></div><div class="jaundice-treatment__content"><h3 class="jaundice-treatment__title title-small">ETCOc is the NEW diagnostic “Gold Standard” test for Jaundice Management.</h3><div class="jaundice-treatment__info"><div class="jaundice-treatment__text text-medium"><p>“The test most deserving of the designation “gold standard” is ETCOc measurement. Moreover, this method is the one we judge best fulfills the AAP 2022 recommendation to ‘identify neonates with hemolysis from any cause’.(Christensen RD et al. J Perinatol. 2023 Jul 19).</p></div><a class="jaundice-treatment__link link link--light-blue" href="cosense-studies.html#test-222">Read More</a></div><div class="jaundice-treatment__info"><div class="jaundice-treatment__text text-medium"><p>According to AAP Guidelines, “ETCOc levels can confirm the presence or absence of hemolysis, and measurement of ETCOc is the only clinical test that provides a direct measurement of the rate of bilirubin production…”</p><p>An elevated level of exhaled ETCOc is a clear indication of active hemolysis that can be measured and monitored non-invasively.</p></div><a class="jaundice-treatment__link link link--light-blue" href="#">Review AAP Guidelines</a></div></div><dialog class="jaundice-treatment__dialog dialog js-modal" aria-labelledby="dialog-header-blood-tests" aria-describedby="dialog-content-blood-tests"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close blood tests modal" title="Close blood tests modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content dialog__modal-content--blood-tests"><div class="dialog__modal-inner"><h3 class="dialog__modal-title visually-hidden" id="dialog-header-blood-tests">Inadequacy of DAT Testing in Diagnosing Hemolytic Conditions in Infants</h3><div class="dialog__modal-text text-medium" id="dialog-content-blood-tests"><p>Commonly used invasive blood tests to determine if a baby is hemolyzing include coombs/DAT, CBC, Reticulocyte count, peripheral smear, Type RH, G6PD. These tests either indirectly measure bilirubin production or attempt to identify a cause of hemolysis and are often inaccurate or unable to diagnose hemolytic conditions.</p><p>According to peer-reviewed evidence from <a href="cosense-studies.html#test-232">Ruparel</a> , <a href="cosense-studies.html#test-231">Elsaie</a> , <a href="cosense-studies.html#test-232">Schutzman</a> , and <a href="cosense-studies.html#test-173">Christensen</a> , DAT testing is inadequate. Positive patients typically receive unnecessary phototherapy while DAT negative patients are often sent home with an undiagnosed hemolytic condition.</p></div></div></div></dialog></div></section><section class="researches"><div class="researches__container container"><div class="researches__content"><h2 class="researches__title title-small">More than 20 years of best practice clinical evidence supports ETCOc testing for jaundice management.</h2><div class="researches__text text-medium"><p>Published data show that ETCOc testing provides a more accurate measure of hemolysis than blood testing. More than a dozen clinical studies have validated the ability of the <i>CoSense <span>®</span> </i>ETCOc Monitor to detect the rate of hemolysis in newborns. As a result, the Academy of American Pediatrics (AAP) recommends ETCOc testing to measure bilirubin production rates in newborns.</p></div><a class="researches__link link link--yellow" href="products.html">Review the Clinical Evidence</a></div><div class="researches__images"><picture><source srcset="./img/researches-img/researches-image.webp" type="image/webp"><img loading="lazy" src="./img/researches-img/researches-image.jpg" class="researches__image" width="746" height="586" alt="The doctor's checking the labs"></picture></div></div></section><section class="consultants"><div class="consultants__container container"><aside class="consultants__aside"><h2 class="consultants__title title-huge">Our clinical advisors</h2></aside><div class="consultants__items"><div class="consultants__swiper swiper"><div class="swiper-wrapper"><div class="swiper-slide"><picture><source srcset="./img/consultants-img/consultants-image-1.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-1.jpg" class="consultants-image" width="300" height="300" alt="Timothy M. Bahr MS, MD"></picture><h3 class="consultants__name">Dr. Timothy M. Bahr, MD, MS</h3><div class="consultants__description text-medium"><p>Assistant Professor of Pediatrics Intermountain Health, University of Utah.</p></div><button class="consultants__button link link--stroke js-open-modal" type="button" aria-label="Open modal" title="Open modal">Learn More</button></div><div class="swiper-slide"><picture><source srcset="./img/consultants-img/consultants-image-2.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-2.jpg" class="consultants-image" width="300" height="300" alt="Anthony E. Burgos, MD, MPH"></picture><h3 class="consultants__name">Dr. Anthony E. Burgos, MD, MPH</h3><div class="consultants__description text-medium"><p>Co-Founder and President of Bilitool, Inc. Associate Professor, of Clinical Science and Health Systems Science at Kaiser Permanente Bernard J. Tyson School of Medicine</p></div><button class="consultants__button link link--stroke js-open-modal" type="button" aria-label="Open modal" title="Open modal">Learn More</button></div><div class="swiper-slide"><picture><source srcset="./img/consultants-img/consultants-image-3.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-3.jpg" class="consultants-image" width="300" height="300" alt="Robert D. Christensen, MD"></picture><h3 class="consultants__name">Dr. Robert D. Christensen, MD</h3><div class="consultants__description text-medium"><p>Director of Neonatal Research at Intermountain Healthcare and Director of the Intermountain Healthcare Clinical Neonatology Program, Northern region.</p></div><button class="consultants__button link link--stroke js-open-modal" type="button" aria-label="Open modal" title="Open modal">Learn More</button></div><div class="swiper-slide"><picture><source srcset="./img/consultants-img/consultants-image-4.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-4.jpg" class="consultants-image" width="300" height="300" alt="Dr. David L. Schutzman MD"></picture><h3 class="consultants__name">Dr. David L. Schutzman, MD</h3><div class="consultants__description text-medium"><p>Neonatologist at Jefferson Einstein Medical Center in Philadelphia</p></div><button class="consultants__button link link--stroke js-open-modal" type="button" aria-label="Open modal" title="Open modal">Learn More</button></div><div class="swiper-slide"><picture><source srcset="./img/consultants-img/consultants-image-5.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-5.jpg" class="consultants-image" width="300" height="300" alt="Dr. David K. Stevenson, MD"></picture><h3 class="consultants__name">Dr. David K. Stevenson, MD</h3><div class="consultants__description text-medium"><p>Professor of Pediatrics.</p></div><button class="consultants__button link link--stroke js-open-modal" type="button" aria-label="Open modal" title="Open modal">Learn More</button></div></div></div><div class="consultants__dialogs"><dialog class="consultants__dialog dialog js-modal" aria-labelledby="dialog-header-consultants-one" aria-describedby="dialog-content-consultants-one"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close modal" title="Close modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content"><div class="dialog__modal-info dialog__modal-info--consultants"><picture><source srcset="./img/consultants-img/consultants-image-1.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-1.jpg" class="consultants-image" width="300" height="300" alt="Timothy M. Bahr MS, MD"></picture><h4 class="dialog__modal-name" id="dialog-header-consultants-one">Dr. Timothy M. Bahr, MD, MS</h4><div class="dialog__modal-description"><p>Assistant Professor of Pediatrics Intermountain Health, University of Utah.</p></div></div><div class="dialog__modal-text dialog__modal-text--consultants text-medium" id="dialog-content-consultants-one"><p>Dr. Bahr is a neonatologist and Assistant Professor of Pediatrics at Intermountain Health and the University of Utah. Dr. Bahr completed medical school at the University of Iowa and his pediatrics residency at Phoenix Children's Hospital. He completed his fellowship in neonatology and neonatal hematology with Drs. Robert Christensen and Robin Ohls at the University of Utah in Salt Lake City, UT. Dr. Bahr’s research and clinical interests are in hematologic disorders of neonates. He has published extensive clinical and translational research in areas such as (1) the management and diagnosis of neonates with hyperbilirubinemia; (2) preventing, detecting, and managing iron deficiency in preterm neonates; and (3) improving neonatal transfusion practices.</p></div></div></dialog><dialog class="consultants__dialog dialog js-modal" aria-labelledby="dialog-header-consultants-two" aria-describedby="dialog-content-consultants-two"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close modal" title="Close modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content"><div class="dialog__modal-info dialog__modal-info--consultants"><picture><source srcset="./img/consultants-img/consultants-image-2.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-2.jpg" class="consultants-image" width="300" height="300" alt="Anthony E. Burgos, MD, MPH"></picture><h4 class="dialog__modal-name" id="dialog-header-consultants-two">Dr. Anthony E. Burgos, MD, MPH</h4><div class="dialog__modal-description"><p>Associate Professor, Clinical Science Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, and regional coordinator for normal newborn care at Kaiser Permanente Downey Medical Center.</p></div></div><div class="dialog__modal-text dialog__modal-text--consultants text-medium" id="dialog-content-consultants-two"><p>Dr. Anthony E. Burgos, MD, MPH is the Co-Founder and President of Bilitool, Inc., the most widely used website for the management of hyperbilirubinemia in newborns. He is the Co-Founder and former Managing Director of the Better Outcomes for Newborns (BORN) research network of the Academic Pediatric Association. He is currently an Associate Professor of Clinical Science and Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine. He is widely published in the areas of newborn jaundice and newborn standards of care. He is committed to identifying and integrating innovation, building consensus, and improving practice standards to make a measurable difference in healthcare.</p></div></div></dialog><dialog class="consultants__dialog dialog js-modal" aria-labelledby="dialog-header-consultants-three" aria-describedby="dialog-content-consultants-three"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close modal" title="Close modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content"><div class="dialog__modal-info dialog__modal-info--consultants"><picture><source srcset="./img/consultants-img/consultants-image-3.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-3.jpg" class="consultants-image" width="300" height="300" alt="Robert D. Christensen, MD"></picture><h4 class="dialog__modal-name" id="dialog-header-consultants-three">Dr. Robert D. Christensen, MD</h4><div class="dialog__modal-description"><p>Director of Neonatal Research at Intermountain Healthcare and Director of the Intermountain Healthcare Clinical Neonatology Program, Northern region.</p></div></div><div class="dialog__modal-text dialog__modal-text--consultants text-medium" id="dialog-content-consultants-three"><p>Dr. Christensen, a pro bono advisor, is the Director of Neonatal Research at Intermountain Healthcare and Director of the Intermountain Healthcare Clinical Neonatology Program for the northern region, where the majority of his research work is focused on observational and interventional clinical studies of neonatal clinical hematology and transfusion medicine. Dr. Christensen held positions including Professor of Pediatrics at the University of Utah School of Medicine, the University of Florida College of Medicine, and the University of South Florida College of Medicine, and was Physician-in-Chief at All Children’s Hospital in St. Petersburg, Florida. He has been a member of the NIH National Heart, Lung and Blood Institute, NIH National Institute of Child Health and Human Development, and National Foundation March of Dimes, was on the executive committee of Thrasher Research Fund, and was sub-committee chair of the American Academy of Pediatrics. He has authored over 300 publications.</p></div></div></dialog><dialog class="consultants__dialog dialog js-modal" aria-labelledby="dialog-header-consultants-four" aria-describedby="dialog-content-consultants-four"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close modal" title="Close modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content"><div class="dialog__modal-info dialog__modal-info--consultants"><picture><source srcset="./img/consultants-img/consultants-image-4.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-4.jpg" class="consultants-image" width="300" height="300" alt="Dr. David L. Schutzman MD"></picture><h4 class="dialog__modal-name" id="dialog-header-consultants-four">Dr. David L. Schutzman, MD</h4><div class="dialog__modal-description"><p>Neonatologist at Jefferson Einstein Medical Center in Philadelphia</p></div></div><div class="dialog__modal-text dialog__modal-text--consultants text-medium" id="dialog-content-consultants-four"><p>Dr. Schutzman is a neonatologist at Jefferson Einstein Medical Center in Philadelphia. Dr. Schutzman completed medical school, a Pediatric residency, and a fellowship in Neonatal-Perinatal Medicine at Jefferson Medical College. While his career has primarily been clinical in nature, he has published on multiple topics relevant to newborns. Most recently, he has focused his research on hyperbilirubinemia of the newborn and its management.</p></div></div></dialog><dialog class="consultants__dialog dialog js-modal" aria-labelledby="dialog-header-consultants-five" aria-describedby="dialog-content-consultants-five"><div class="dialog__modal-close js-close-modal"><button class="dialog__modal-btn" type="button" aria-label="Close modal" title="Close modal"><svg class="dialog__modal-icon"><use xlink:href="./img/sprite.svg#modal-close-icon"></use></svg></button></div><div class="dialog__modal-content"><div class="dialog__modal-info dialog__modal-info--consultants"><picture><source srcset="./img/consultants-img/consultants-image-5.webp" type="image/webp"><img loading="lazy" src="./img/consultants-img/consultants-image-5.jpg" class="consultants-image" width="300" height="300" alt="Dr. David K. Stevenson, MD"></picture><h4 class="dialog__modal-name" id="dialog-header-consultants-five">Dr. David K. Stevenson, MD</h4><div class="dialog__modal-description"><p>Professor of Pediatrics.</p></div></div><div class="dialog__modal-text dialog__modal-text--consultants text-medium" id="dialog-content-consultants-five"><p>Dr. David K. Stevenson, MD, is the Harold K. Faber Professor of Pediatrics and has made many impactful contributions to the field of pediatrics. As a neonatologist, his research has focused primarily on neonatal jaundice, with special expertise in carbon monoxide detection for estimating total bilirubin production, and more recently on the causes of preterm birth and its prevention. He has held numerous leadership roles at Stanford University School of Medicine, including Vice Dean and Senior Associate Dean for Academic Affairs, Senior Associate Dean for Maternal &amp; Child Health, Co-Director of the Stanford Maternal &amp; Child Health Research Institute, Co-Director of the Metabolic Health Center, and Principal Investigator for the March of Dimes Prematurity Research Center at Stanford University. Dr. Stevenson has received many awards, including the Virginia Apgar Award, the highest award in Perinatal Pediatrics, the Joseph W. St. Geme, Jr. Leadership Award from the Federation of Pediatric Organizations, the Jonas Salk Award for Leadership in Prematurity Prevention from the March of Dimes Foundation, and the John Howland Medal and Award, the highest award given by the American Pediatric Society. He has served as the President of the American Pediatric Society. In recognition of his achievements, Dr. Stevenson is a member of the National Academy of Medicine.</p></div></div></dialog></div></div></div></section></main><footer class="footer"><div class="footer__container container"><div class="footer__logo"><a class="footer__logo-link" href="index.html"><img class="footer__logo-image" src="./img/logo-footer.svg" width="174" height="39" alt="Capnia logo"></a></div><div class="footer__wrapper"><div class="footer__customer"><ul class="footer__social"><li class="footer__social-item"><a class="footer__social-link footer-link" href="privacy-statement.html">Customer Support</a></li><li class="footer__social-item"><a class="footer__social-link footer-link" href="https://www.linkedin.com/company/capnia-inc./jobs/" target="_blank">Careers</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--follow footer-link" href="https://www.linkedin.com/company/capnia-inc./about/" target="_blank">Follow Us</a></li><li class="footer__social-item"><a class="footer__social-link bilitool footer-link" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></li></ul></div><div class="footer__contact"><a class="footer__contact-link footer-link" href="#">Contact Us</a><address class="footer__contact-address footer-contact-item footer-contact-item--address">1101 Chess Drive Foster City, CA 94404</address><a class="footer__contact-tel footer-contact-item footer-contact-item--tel" href="tel:8664323788"><span class="footer__contact-text">Tel:</span> <span class="footer__contact-descr">(866) 432-3788</span> </a><a class="footer__contact-email footer-contact-item footer-contact-item--email" href="mailto:info@capnia.com"><span class="footer__contact-text">Email:</span> <span class="footer__contact-descr footer__contact-descr--email">info@capnia.com</span></a></div><a class="bilitool bilitool--mobile" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></div><div class="footer__info"><div class="footer__info-content"><span class="footer__info-item">CAPNIA, Inc. © 2024</span> <span class="footer__info-item">All Rights Reserved</span></div><div class="footer__info-content"><a class="footer__info-item" href="terms-of-use.html">Terms of Use</a> <a class="footer__info-item" href="privacy-statement.html">Privacy Statement</a></div></div></div></footer></div></body></html>